Navigation Links
Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013

Indian Oncologists Are Starting to Embrace Use of Targeted Agents Despite Their High Cost, According to a Report from Decision Resources

WALTHAM, Mass., April 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Sanofi-Aventis' Eloxatin, Indian brand/generics (oxaliplatin) and Roche/Chugai's Xeloda, Indian brand/generics (capecitabine) will dominate the Indian colorectal cancer drug market through 2013. However, as a result of the increased use of targeted agents and rapid growth of the Indian colorectal cancer drug market the combined market share of these two drugs will fall from 67 percent in 2008 to 52 percent in 2013.

The new Emerging Markets report entitled Colorectal Cancer in India also finds that Indian oncologists are starting to embrace use of targeted agents such as Roche/Chugai's Avastin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) despite their high cost. Growth of these agents and the launch of Amgen's Vectibix (panitumumab) will ensure that sales of targeted agents rise from $3.1 million in 2008 to $13.5 million in 2013.

"The increased use of targeted agents like Avastin and Erbitux is due to the increasing wealth and urbanization among India's population and because their efficacy and toxicity are superior to those of conventional therapies," stated Marcus Hoyle, analyst at Decision Resources.

About Emerging Markets Reports

Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
2. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
3. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
4. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
5. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Delivers 2008 Results Above Guidance
7. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
8. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
10. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
11. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
Post Your Comments:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: